UA72777C2 - A process for the preparation of amorphous atorvastatin calcium - Google Patents
A process for the preparation of amorphous atorvastatin calcium Download PDFInfo
- Publication number
- UA72777C2 UA72777C2 UA2002054059A UA2002054059A UA72777C2 UA 72777 C2 UA72777 C2 UA 72777C2 UA 2002054059 A UA2002054059 A UA 2002054059A UA 2002054059 A UA2002054059 A UA 2002054059A UA 72777 C2 UA72777 C2 UA 72777C2
- Authority
- UA
- Ukraine
- Prior art keywords
- atorvastatin
- amorphous
- calcium
- atorvastatin calcium
- mixture
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title claims abstract description 27
- 229960001770 atorvastatin calcium Drugs 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract description 20
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960005370 atorvastatin Drugs 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
- 238000001953 recrystallisation Methods 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- BWFCZHDTTAYGNN-CNZCJKERSA-N calcium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound [Ca].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 BWFCZHDTTAYGNN-CNZCJKERSA-N 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 159000000007 calcium salts Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903634A HU226640B1 (en) | 1999-10-18 | 1999-10-18 | Process for producing amorphous atorvastatin calcium salt |
| PCT/HU2000/000106 WO2001028999A1 (en) | 1999-10-18 | 2000-10-17 | Process for the preparation of amorphous atorvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72777C2 true UA72777C2 (en) | 2005-04-15 |
Family
ID=90014241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002054059A UA72777C2 (en) | 1999-10-18 | 2000-10-17 | A process for the preparation of amorphous atorvastatin calcium |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1235800B1 (cs) |
| JP (1) | JP2003512354A (cs) |
| KR (1) | KR100664353B1 (cs) |
| CN (1) | CN1157374C (cs) |
| AT (1) | ATE345327T1 (cs) |
| AU (1) | AU1166301A (cs) |
| CA (1) | CA2388018C (cs) |
| CZ (1) | CZ300071B6 (cs) |
| DE (1) | DE60031882T2 (cs) |
| HR (1) | HRP20020334B1 (cs) |
| HU (1) | HU226640B1 (cs) |
| PL (1) | PL354604A1 (cs) |
| RS (1) | RS50473B (cs) |
| RU (1) | RU2255932C2 (cs) |
| SK (1) | SK286861B6 (cs) |
| UA (1) | UA72777C2 (cs) |
| WO (1) | WO2001028999A1 (cs) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| DE10135493A1 (de) * | 2001-07-20 | 2003-01-30 | Jobst Krauskopf | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
| HRP20040077A2 (en) | 2001-07-30 | 2004-06-30 | Reddys Lab Ltd Dr | Crystalline forms vi and vii of atorvastatin-calcium |
| AU2002247944B2 (en) * | 2002-03-18 | 2009-05-21 | Biocon Limited | Amorphous Hmg-CoA reductase inhibitors of desired particle size |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| US7994343B2 (en) | 2004-03-17 | 2011-08-09 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| US20070225353A1 (en) * | 2004-04-16 | 2007-09-27 | Pfizer, Inc. | Process for Forming Amorphous Atorvastatin |
| CN1692906A (zh) * | 2004-04-30 | 2005-11-09 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
| EP1745020A2 (en) | 2004-05-05 | 2007-01-24 | Pfizer Products Incorporated | Salt forms of atorvastatin |
| HUE029911T2 (en) * | 2004-07-16 | 2017-04-28 | Lek Pharmaceuticals | Products of atorvastatin calcium oxidative degradation |
| CA2754932C (en) | 2004-07-20 | 2014-04-01 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US7674923B2 (en) * | 2004-09-28 | 2010-03-09 | Teva Pharmaceutical Industries Ltd | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| TW200630335A (en) * | 2004-10-18 | 2006-09-01 | Teva Pharma | Processes for preparing amorphous atorvastatin hemi-calcium |
| NZ554541A (en) | 2004-10-28 | 2011-01-28 | Warner Lambert Co | Process for forming amorphous atorvastatin |
| PT1957452E (pt) | 2005-11-21 | 2010-05-25 | Warner Lambert Co | Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN103274985B (zh) * | 2010-12-03 | 2016-03-09 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| ATE123020T1 (de) * | 1990-05-11 | 1995-06-15 | American Cyanamid Co | N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe. |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| AU714735B2 (en) * | 1996-09-20 | 2000-01-13 | Meiji Seika Pharma Co., Ltd. | A crystalline substance of cefditoren pivoxyl and the production of the same |
-
1999
- 1999-10-18 HU HU9903634A patent/HU226640B1/hu not_active IP Right Cessation
-
2000
- 2000-10-17 AU AU11663/01A patent/AU1166301A/en not_active Abandoned
- 2000-10-17 EP EP00973115A patent/EP1235800B1/en not_active Expired - Lifetime
- 2000-10-17 DE DE60031882T patent/DE60031882T2/de not_active Expired - Fee Related
- 2000-10-17 UA UA2002054059A patent/UA72777C2/uk unknown
- 2000-10-17 RU RU2002113564/04A patent/RU2255932C2/ru not_active IP Right Cessation
- 2000-10-17 CN CNB008144583A patent/CN1157374C/zh not_active Expired - Fee Related
- 2000-10-17 KR KR1020027004906A patent/KR100664353B1/ko not_active Expired - Fee Related
- 2000-10-17 WO PCT/HU2000/000106 patent/WO2001028999A1/en active IP Right Grant
- 2000-10-17 CZ CZ20021256A patent/CZ300071B6/cs not_active IP Right Cessation
- 2000-10-17 SK SK519-2002A patent/SK286861B6/sk not_active IP Right Cessation
- 2000-10-17 HR HR20020334A patent/HRP20020334B1/xx not_active IP Right Cessation
- 2000-10-17 PL PL00354604A patent/PL354604A1/xx not_active Application Discontinuation
- 2000-10-17 AT AT00973115T patent/ATE345327T1/de not_active IP Right Cessation
- 2000-10-17 CA CA002388018A patent/CA2388018C/en not_active Expired - Fee Related
- 2000-10-17 JP JP2001531799A patent/JP2003512354A/ja active Pending
- 2000-10-17 RS YUP-283/02A patent/RS50473B/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| YU28302A (sh) | 2005-06-10 |
| EP1235800B1 (en) | 2006-11-15 |
| HU226640B1 (en) | 2009-05-28 |
| HRP20020334B1 (hr) | 2007-12-31 |
| SK286861B6 (sk) | 2009-06-05 |
| HRP20020334A2 (en) | 2004-02-29 |
| SK5192002A3 (en) | 2002-11-06 |
| ATE345327T1 (de) | 2006-12-15 |
| HK1050199A1 (en) | 2003-06-13 |
| HUP9903634D0 (en) | 1999-12-28 |
| RS50473B (sr) | 2010-03-02 |
| CA2388018C (en) | 2008-04-08 |
| CN1379760A (zh) | 2002-11-13 |
| EP1235800A1 (en) | 2002-09-04 |
| HUP9903634A3 (en) | 2002-01-28 |
| AU1166301A (en) | 2001-04-30 |
| CZ20021256A3 (cs) | 2002-08-14 |
| CA2388018A1 (en) | 2001-04-26 |
| WO2001028999A1 (en) | 2001-04-26 |
| KR20020063166A (ko) | 2002-08-01 |
| DE60031882T2 (de) | 2007-07-05 |
| CN1157374C (zh) | 2004-07-14 |
| DE60031882D1 (de) | 2006-12-28 |
| RU2255932C2 (ru) | 2005-07-10 |
| PL354604A1 (en) | 2004-01-26 |
| KR100664353B1 (ko) | 2007-01-02 |
| HUP9903634A2 (hu) | 2001-12-28 |
| CZ300071B6 (cs) | 2009-01-21 |
| JP2003512354A (ja) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA72777C2 (en) | A process for the preparation of amorphous atorvastatin calcium | |
| RU2126397C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ТРИГИДРАТА (2R, 3S)-3-ТРЕТ-БУТОКСИ-КАРБОНИЛАМИНО-2-ГИДРОКСИ-3- ФЕНИЛПРОПИОНАТА-4-АЦЕТОКСИ -2α- БЕНЗОИЛОКСИ -5β, 20-ЭПОКСИ -1,7β,10β- ТРИГИДРОКСИ-9-ОКСО- ТАКС-11-ЕН-13α-ИЛА | |
| DE69911774T2 (de) | Paroxetinmethansulfonat-acetonitrilsolvat 1:1 | |
| UA51699C2 (uk) | Спосіб одержання магнієвої солі заміщеного сульфінілом гетероциклу | |
| JP2001500521A (ja) | セフジトレン ピボキシル結晶性物質及びその製造法 | |
| SI20305A (sl) | Kristali natrijeve soli pravastatina | |
| SU799666A3 (ru) | Способ получени гидратированной крис-ТАлличЕСКОй фОРМы НАТРиЕВОй СОли 3-АцЕТОКСи-МЕТил-7 2-(2-АМиНО-4-ТиАзОлил)-2-МЕТОКСи-иМиНОАцЕТАМидО цЕф-3-EM-4-КАРбОНОВОй КиС-лОТы,СиН-изОМЕРА | |
| JP2001500877A (ja) | オランザピンの製造方法および中間体 | |
| KR20010020423A (ko) | 결정형 마크로리드 및 이들의 제조방법 | |
| UA46723C2 (uk) | 5-ацетамідо-2,3,4,5-тетрадеокси-4-гуанідино-d-гліцеро-d-галактонон-2-єнопіранозонова кислота у кристалічній формі, спосіб її отримання, антивірусна фармацевтична композиція і спосіб її отримання | |
| PT753518E (pt) | Processos para a preparacao de uma forma cristalizada em particulas de cloridrato de zilpaterol e produtos intermediarios utilizados | |
| WO2003087039A1 (fr) | Nouveau cristal de nateglinide | |
| WO2007074475A2 (en) | Novel polymorphic forms of ibandronate | |
| IL101705A (en) | Acetone, 1-butanol 1-propanol and 2-propanol solvates of dirithromycin and process for their preparation | |
| US5399686A (en) | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate | |
| JPH02180882A (ja) | β―ラクタム抗生物質の溶媒和物 | |
| EP0627430B1 (en) | Process for converting loracarbef dihydrate to loracarbef monohydrate | |
| RU2160261C2 (ru) | Кристаллическая безводная форма лоракарбефа и способ получения моногидрата лоракарбефа (варианты) | |
| JP2009514833A (ja) | 滅菌医薬粉末化合物の調製方法 | |
| JP2004256448A (ja) | ６−ヒドロキシ−２−ナフトエ酸の脱色方法 | |
| IE55433B1 (en) | Process for the manufacture of crystalline sodium cefoperazone | |
| HU189186B (en) | Process for producing hydrochloride of 3-cepheme-4-carboxylic acid and for purifying contaminated material by them | |
| RU2830121C2 (ru) | Способ получения фармацевтической композиции | |
| CN114269743A (zh) | 6-氟-9-甲基-9H-β-咔啉的稳定的多晶型物及其用途 | |
| UA60369C2 (uk) | Спосіб одержання високодисперсного порошку гідроксилапатиту |